Which hips are still worth repairing

At Lincolnshire Hip, this decision can usually be reduced to one gatekeeping question: is there a focal, symptomatic defect in a still-viable hip joint, or is the problem broader joint failure? Repair is more relevant when the damage is contained and joint space is still preserved. That matters more than any single scan phrase. A 2017 review of hip chondral defects stated that when Tönnis grade reaches 2 or higher, cartilage-restoration treatment should be considered ineffective, and a 2021 ChondroFiller cohort likewise reported poor results in patients with Tönnis 2–3 osteoarthritis, with 2 patients progressing to total hip replacement.

Age helps frame the discussion, but date of birth is not the whole story. Hip preservation studies mainly involve younger adults with preserved joint space: the UK REPAIR pilot, for example, is studying adults aged 18–40 with full-thickness acetabular defects. Defect size then helps guide technique choice in the hip joint. Older microfracture was mainly used for smaller grade 3–4 lesions under 2 cm², while AMIC or related restoration approaches are more often discussed for symptomatic full-thickness defects of 2 cm² or more. In selected non-arthritic hips, ChondroFiller may also be considered, but the hip evidence for it remains more limited than for AMIC.

When hip replacement is the better route

By the time hip pain is disturbing sleep, shrinking walking distance and making simple tasks such as stairs or getting in and out of a car difficult, hip replacement is often the more reliable discussion. NHS guidance says a replacement may be recommended when hip pain and stiffness are having a big effect on life and other treatments have not worked, most commonly because of osteoarthritis. At this stage, the decisive issue is day-to-day function in the whole hip joint rather than another debate about lesion size on MRI.

A large focal defect on its own does not automatically mean replacement, and some younger adults with contained cartilage lesions are still considered for preservation. But when the hip is globally worn, stiff and losing joint space, preserving the native joint at any cost may be less predictable than replacing it. That balance often shifts further towards replacement with increasing age, because NHS osteoarthritis risk rises over time and published AMIC series in the hip mainly involve adults with mean ages of roughly 34 to 45 years rather than older arthritic hips. In the Lincolnshire Hip pathway, saying that replacement is the more realistic route is not a failure of treatment; it is often the clearest way to restore function in an arthritic hip joint.

How AMIC compares with older microfracture in the hip

The practical takeaway is that AMIC is meant to make an older microfracture-style repair in the hip joint more durable, not simply more elaborate. In the UK REPAIR pilot, adults aged 18–40 with full-thickness acetabular defects are being compared between microfracture alone and AMIC, which adds a collagen patch over the marrow-stimulation clot. That places AMIC in a useful middle ground at Lincolnshire Hip: it is still a single-stage preservation procedure, but it goes further than simple marrow stimulation when a focal lesion needs something more robust than microfracture on its own.

The reason that matters is the quality of the repair response. A hip technique paper published in 2021 noted that isolated microfracture remains common for smaller defects, but it produces fibrocartilage rather than native hyaline cartilage, and benefit may become less predictable after 2 to 3 years. By contrast, a 2024 systematic review covering 209 hips found significant postoperative improvement after AMIC, and in the comparative studies there were 0 conversions to total hip arthroplasty after AMIC versus 2% to 32.6% after microfracture alone. An updated 2023 review reported survival ranges of 92.9% to 100% for AMIC, compared with 59.1% to 100% for microfracture. Those figures do not make AMIC right for every hip, but they help explain why selected younger adults with full-thickness focal lesions are often steered towards AMIC before more complex cell-based repair is discussed.

Where ChondroFiller fits in hip repair

ChondroFiller, sometimes described as Liquid Cartilage, is a one-step arthroscopic, cell-free collagen scaffold used for symptomatic full-thickness cartilage defects in the hip joint. The more useful question here is not the general repair-versus-replacement split already covered, but what this scaffold is meant to do in a selected hip: it is placed to support cartilage-like repair in a focal defect rather than to rescue a broadly worn joint. A 2021 hip technique paper still described microfracture as common for smaller lesions, but noted concerns that the repair tissue is fibrocartilage and that benefit may become less predictable after 2 to 3 years.

The direct hip evidence for ChondroFiller remains limited. In a 2021 prospective cohort, 26 adults with femoroacetabular impingement and acetabular defects larger than 2 cm² were treated; of the 21 reviewed at 3 to 5 years, 17 had good or excellent results. That is encouraging, but it is not proof of reliable success across every damaged hip joint. The same study reported poor results in Tönnis 2–3 osteoarthritis, and 2 patients progressed to total hip replacement. Compared with AMIC, the evidence base is thinner: a 2023 systematic review found only a single ChondroFiller hip study versus a broader AMIC literature. For Lincolnshire Hip, that supports a cautious, MRI-led discussion when imaging suggests a focal repair target, while recognising that long-term durability and ideal size limits are still less certain than with AMIC.

What hip risks and recovery usually involve

Recovery after hip joint cartilage repair is often more protected than many people expect. Published review material suggests that after AMIC, full weight bearing is commonly avoided for about 4 weeks, with partial loading used first. In practical terms, the opening phase may involve crutches, careful walking and supervised physiotherapy rather than a quick return to normal activity. Protocols are not identical across every hip procedure, particularly when cartilage work is combined with arthroscopic treatment for femoroacetabular impingement in the same operation.

After that early protection phase, rehabilitation usually shifts towards restoring gait, hip movement and strength without overloading the repair. At Lincolnshire Hip, the realistic aim is symptom improvement and better day-to-day function in the hip joint, not a promise that every patient returns to unrestricted sport. The most common disappointment in real life is often not a dramatic complication, but a hip that stays sore, stiff or limited for longer than hoped.

Durability also needs plain language. In the 2021 ChondroFiller hip cohort, 2 of 26 patients progressed to total hip replacement within 3 to 5 years, and poorer results were reported when background osteoarthritis was already present. A 2023 systematic review found only a single hip ChondroFiller study, whereas AMIC had a broader evidence base, so longer-term revision patterns remain less certain for ChondroFiller than for AMIC.

How the Lincolnshire Hip pathway works

Set aside geography and booking details: the useful pathway is clinical. In UK practice, a hip decision usually begins with specialist assessment and imaging, with MRI becoming especially useful when the pattern suggests a focal problem inside the hip joint rather than straightforward arthritis alone. The point of that stage is to define the problem clearly before treatment is chosen, not to assume that every painful hip belongs on the same track.

If imaging shows a discrete cartilage lesion, the next discussion may be about preservation procedures such as AMIC or, in selected settings, ChondroFiller. Access is not yet standardised across the UK. The HRA-registered REPAIR pilot, for example, is studying adults aged 18 to 40 and comparing AMIC with microfracture, which reflects the fact that referral routes, funding and waiting patterns can still vary. Once a plan is agreed, the pathway is usually imaging review, procedure where appropriate, then supervised rehabilitation and follow-up.

For a local route into that process, Lincolnshire Hip offers direct-access assessment for hip and groin problems without GP referral, and its published pathway emphasises consultation, imaging where needed and follow-up rather than surgery in isolation. If hip pain and imaging suggest a focal hip joint problem, Lincolnshire Hip can assess whether preservation or replacement is the more realistic route.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002